Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 841 across all filing types
Latest filing 2013-08-28 Legal Proceedings Report
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Orexo reports successful completion of OX51 phase II dose-finding study in prevention of procedure-induced pain
Legal Proceedings Report Classification · 1% confidence The document is titled 'Press release' and announces the 'successful completion of OX51 phase II dose-finding study'. It details clinical trial results, safety profiles, market potential, and next steps (consulting regulatory agencies). This structure—a formal announcement of clinical/research progress and business updates outside of standard periodic financial reports (10-K, IR) or formal voting results—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release detailing specific operational/clinical news rather than just summarizing quarterly financials (ER) or being a miscellaneous filing (RNS), and it doesn't fit any other specific category like M&A (TAR) or Capital Change (CAP), it most closely aligns with an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it's not tied to a specific reporting period. Given the focus on clinical trial success and future regulatory consultation, it functions as a significant operational update. However, since it is not explicitly an 'Earnings Release' summarizing P&L, and it is a general announcement, the most appropriate general category for significant, non-standard operational news that must be made public is often RNS, but ER is used for initial results announcements. Since this is a clinical trial result announcement, which is a key operational milestone, and it is structured like a typical press release, I will classify it as an Earnings Release (ER) as these often contain operational/clinical highlights alongside or instead of pure financial figures, or as RNS if it's purely operational. Given the options, ER is often used for major operational news releases. However, upon re-evaluation against the definitions, this is a specific clinical trial update, not a standard earnings report. It is a significant announcement that must be made public. It fits best as a general Regulatory Filing (RNS) as it is a press release announcing a material event, or potentially an Investor Presentation (IP) if it were a slide deck, but it is text. Given the lack of a specific category for 'Clinical Trial Results Announcement', RNS serves as the best fallback for material, non-standard regulatory disclosures made via press release. I will lean towards RNS as the most accurate fallback for a material, non-periodic operational announcement.
2013-08-28 English
Orexo meddelar att OX51 fas II-studie för förebyggande av smärta i samband med ingrepp avslutats
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces the completion of a Phase II study for a drug candidate (OX51) and positive results regarding pain relief. It discusses clinical trial details, market potential, and future regulatory consultation. This type of announcement, detailing significant operational or clinical milestones outside of routine financial reporting (like 10-K or quarterly results), is typically classified as a general corporate announcement or regulatory filing. Since it is a press release announcing a major development (study completion and positive results) and not a formal financial report (like ER, IR, or 10-K), nor a specific transaction (like DIV, SHA, POS), the most appropriate category is the general regulatory/corporate announcement fallback, RNS, especially given its brevity and nature as a public disclosure required by financial instrument laws ("Orexo är skyldigt att offentliggöra informationen i detta pressmeddelande enligt lagen om handel med finansiella instrument"). It is not an Earnings Release (ER) as it focuses on R&D progress, not period financials.
2013-08-28 Swedish
Orexo AB konverterar konvertibellån från Novo A/S
Capital/Financing Update Classification · 1% confidence The document is a press release ("Pressmeddelande") dated August 26, 2013, announcing that Orexo AB is converting a convertible loan from Novo A/S into shares. This action directly impacts the company's capital structure (increasing shares and equity, reducing interest costs). This falls under the category of updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific financing event.
2013-08-26 Swedish
Orexo AB converts convertible bonds subscribed for by Novo A/S
Capital/Financing Update Classification · 1% confidence The document is a press release dated August 26, 2013, announcing that Orexo AB converted convertible bonds subscribed for by Novo A/S into shares. This action directly impacts the company's capital structure (increasing the number of shares and Novo A/S's ownership percentage) and financial position (increasing equity and decreasing interest expenses). This type of announcement, detailing a financing event that changes the capital structure, aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it details a specific financing/capital structure change, CAP is the most precise fit over the general 'RNS' fallback.
2013-08-26 English
First patient dosed in new study on long-term adherence to treatment of opioid dependence with Zubsolv®
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces a clinical event: "First patient dosed in new study on long-term adherence to treatment of opioid dependence with Zubsolv®". It details the study's scope, expected completion date, and includes quotes from executives and external consultants. This format—a brief announcement of operational or clinical progress, often released via press wire—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a comprehensive financial report (10-K, IR), an audit report (AR), or a specific management discussion (MDA), and it is a direct announcement of company activity rather than a notice about a future report (RPA), it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a reporting period, but it is primarily an operational update. Given the options, RNS serves as the best general category for non-standard, material operational announcements that are not explicitly covered by other codes like DIV, CAP, or MANG. The length (5150 chars) is substantial enough to be more than a simple notification, but it lacks the structure of a formal financial report. I will classify it as RNS as it is a general regulatory announcement/press release.
2013-08-07 English
Första patienten har påbörjat medicineringen i en ny klinisk studie syftande till att fastställa tidiga behandlingseffekter och acceptans för Zubsolv®
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces the initiation of a new clinical study (ISTART) for the drug Zubsolv®. It provides details about the study's objectives, design, and expected impact, along with commentary from the CEO and an expert. This type of announcement, detailing operational or clinical progress, is typically classified as a general regulatory announcement or news release, especially since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management discussion (MDA). Given the options, it fits best as a general Regulatory Filing (RNS) as it is a formal public disclosure of a significant corporate/clinical event, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but as a press release, RNS is the most appropriate general category for non-standard disclosures.
2013-08-07 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.